Study of Promising HIV Vaccine Begins - Diverse Health

Higher Education News and Jobs

Study of Promising HIV Vaccine Begins

Email
   
        


The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus. HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day.

Read More

Comments

Print Friendly

Related Articles

Deadline Extended for Insurers The Trump administration is giving insurance companies an extra three weeks to decide whether to offer insurance plans through the Affordable Care Act markets, and how much to charge. The extension comes as insurance companies wait for President T...
Health Disparities Can Be Skin Deep About half of patients will have skin of color by 2050, the U.S. Census Bureau projects. Of the many ways this demographic change will affect American society, there is one medical implication that is not widely appreciated. Dermatologists and the pr...
Disease Kills Hundreds of N.M. Residents Cerebral cavernous malformation is a genetic disease where blood cells clump together, weakening their walls and causing them to leak blood. When that happens in the brain, it leads to headaches, seizures and potentially death. The vast majority o...
Obamacare Marketplaces Aren’t Collapsing, but They Aren’t Thriving Typically by August, the state of the upcoming Obamacare enrollment season is pretty evident – that is, what health insurance rates will look like and how many insurers will participate in the marketplaces created under the Affordable Care Act. But n...